Sector News

Stryker eyes deals, market share growth in Europe

January 15, 2015
Life sciences
(Reuters) – Orthopedic device and surgical equipment maker Stryker Corp said on Wednesday it is eyeing growth through acquisitions, and has set its sights on improving market share for its products in Europe.
 
Stryker Chief Executive Kevin Lobo, speaking at the JP Morgan healthcare conference in San Francisco, said the company was in a very strong cash position that would allow it to make acquisitions that are “small, medium or even large.”
 
“We need to be market leaders in the areas that we choose to play in,” Lobo said. “We’ll look at deals of all different sizes … to strengthen our position.”
 
Stryker plans to repatriate some $2 billion in cash held overseas in the second half of 2015.
 
The company on Tuesday cautioned that the strength of the U.S. dollar versus overseas currencies would take a larger than previously expected toll on 2015 earnings, shaving some 20 cents from per share profit versus its prior view of 10 to 12 cents.
 
Stryker currently has about two thirds of its total sales in the United States, with about a quarter coming from other developed markets and 8 percent from emerging markets.
 
Lobo sees Europe as a critical area with room for improving Stryker’s performance, and said he believes the capital spending climate there is improving.
 
“Our market shares are dramatically lower in Europe than in the U.S., Canada or Japan,” he said. “Our products should be garnering higher market share there.”
 
Stryker has altered its corporate structure so that operations in Europe will now report directly to the United States.
 
Despite the challenging environment in some emerging markets, such as Russia, Lobo said Stryker aims to increase its percentage of total sales from developing markets “to get to double digits in the next few years.”
 
Stryker shares were down $2.20, or 2.3 percent, at $92.02 on the New York Stock Exchange.
 
(Reporting by Bill Berkrot in New York; Editing by Bernard Orr)

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

How can we help you?

We're easy to reach